Evidence map›Paper›PMID 28652336›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Structure of human nSMase2 reveals an interdomain allosteric activation mechanism for ceramide generation.

Michael V Airola, Prajna Shanbhogue, Achraf A Shamseddine, Kip E Guja, Can E Senkal, Rohan Maini, Nana Bartke, Bill X Wu, Lina M Obeid, Miguel Garcia-Diaz and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Neutral sphingomyelinase 2: A promising drug target for CNS disease.Advances in pharmacology (San Diego, Calif.) · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Sphingolipid metabolism and regulated cell death in malignant melanoma.Apoptosis : an international journal on programmed cell death · 2024
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Michael V AirolaStony Brook University Cancer Center, Stony Brook, NY 11794.
Prajna ShanbhogueDepartment of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794.
Achraf A ShamseddineDepartment of Medicine, Stony Brook University, Stony Brook, NY 11794.
Kip E GujaDepartment of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11794.
Can E SenkalStony Brook University Cancer Center, Stony Brook, NY 11794.
Rohan MainiDepartment of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794.
Nana BartkeDanone Nutricia Research, Singapore 138671.
Bill X WuDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425.
Lina M ObeidStony Brook University Cancer Center, Stony Brook, NY 11794.
Miguel Garcia-DiazDepartment of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11794.
Yusuf A HannunStony Brook University Cancer Center, Stony Brook, NY 11794; yusuf.hannun@stonybrookmedicine.edu.
Stony Brook University · USMedical University of South Carolina · USNorthport VA Medical Center · US

Funding

Neutral Sphingomyelinases and Bioactive CeramidesR35GM118128 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI HANNUN, YUSUF AWNI · 2016 to 2025
$7.9M
Mechanisms of mitochondrial transcriptionR01GM100021 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI GARCIA-DIAZ, MIGUEL · 2012 to 2016
$1.5M
Regulation of Neutral Sphingomyelinase 2 by Inter-Domain InteractionsF32GM100679 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI AIROLA, MICHAEL VIRGIL · 2012 to 2014
$102k
Characterization of an essential mitochondrial rRNA methyltransferaseF30ES022930 · NIEHS · STATE UNIVERSITY NEW YORK STONY BROOK · PI GUJA, KIP E · 2013 to 2014
$95k
NIEHS NIH HHS F30 ES022930NIGMS NIH HHS F32 GM100679NIGMS NIH HHS R01 GM100021NIGMS NIH HHS R35 GM118128
6 · The paper itself

Abstract

Neutral sphingomyelinase 2 (nSMase2, product of the

Indexed as

Allosteric SiteAniline CompoundsBenzylidene CompoundsCatalytic DomainCell MembraneCeramidesCrystallography, X-RayHumansLipidsMCF-7 CellsProtein BindingProtein FoldingSaccharomyces cerevisiaeSignal TransductionSphingomyelin PhosphodiesteraseAniline CompoundsBenzylidene CompoundsCeramidesGW 4869LipidsSMPD3 protein, humanSphingomyelin Phosphodiesteraseceramidecrystallographyenzymelipidsphingomyelinase

Identifiers

PMID28652336
PMCPMC5514751
OpenAlexW2656748229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.